Clinical Trials Logo

Argatroban, Rt-PA clinical trials

View clinical trials related to Argatroban, Rt-PA.

Filter by:
  • None
  • Page 1

NCT ID: NCT03506009 Terminated - Argatroban, Rt-PA Clinical Trials

Argatroban Plus r-tPA for Posterior Circulation Infarction(AR-PCI)

Start date: July 11, 2018
Phase: Phase 4
Study type: Interventional

Acute ischemic stroke (AIS) is the most common type of stroke, which has high rate of morbidity, mortality and disability. A large number of studies have confirmed that the thrombolytic therapy can effectively open blood vessels and improve the functional prognosis of acute ischemic stroke. Therefore, all guidelines recommend giving thrombolysis treatment to acute ischemic stroke patients within 4.5 hours of onset. However, about 1/3 patients receiving thrombolysis will have good prognosis, while a large number of patients will still be disabled and even dead. How to improve the neurofunction prognosis of thrombolytic patients has been a hot topic in the world. Recent studies have found that the combined application of argatroban and rt-PA in the treatment of acute anterior circulation infarction might improve the clinical prognosis and not significantly increase bleeding. Some studies have reported that the combined application of argatroban and rt-PA could improve the blood vessel opening rate, and prevent re-occlusion after opening. Based on the discussion, the present study is designed to explore the efficacy and safety of argatroban plus rt-PA in the treatment of acute posterior circulation infarction.